Clear Labs Inc.
San Carlos, CA
- UEI
- DB92QMA4T9G5
- CAGE
- 8DRN3
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1559 Industrial Rd, San Carlos, CA 94070, USA
- Website
- clearlabs.com
- Founded
- 2014
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $415,518 |
| FY2025 | $404,990 |
| FY2024 | $2,919,812 |
| FY2023 | $304,481 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $415,518 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Executive Office Of The Governor Of Delaware | NU50CK000497 | $1,250,012 | |
| Executive Office Of The Governor Of Delaware | NU50CK000497 | $149,988 | |
| Executive Office Of The Governor Of Delaware | NU50CK000497 | $501,522 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Invitae Corporation | — | 621511 Medical Laboratories |
| Opko Health, Inc. | — | 621511 Medical Laboratories |
| Fulgent Genetics, Inc. | El Monte, CA | 621511 Medical Laboratories |
| Vela Diagnostics USA Inc. | Fairfield, NJ | 423450 Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers |
| Medgenome Inc. | Foster City, CA | 621511 Medical Laboratories |
About the company
Clear Labs Inc. is a for-profit manufacturer and genomic analysis company located in San Carlos, California, specializing in advanced diagnostics and genomic sequencing technologies. The company is registered in SAM.gov and provides sophisticated scientific services primarily focused on COVID-19 genomic sequencing, diagnostic testing, and related technological solutions for federal agencies. Clear Labs leverages its proprietary DX analyzer platform to deliver high-precision genomic analysis and testing capabilities across multiple federal health and research domains.
Through federal contract awards, Clear Labs Inc. has provided extensive COVID-19 genomic sequencing services and related products to multiple federal agencies, with a primary focus on the Department of Veterans Affairs (VA). The company's contract awards have included delivering reagents, consumables, automation tools, software licenses, and instrument systems for genomic sequencing and testing. Notably, the contract awards ranged from small purchase orders of $4,500 to significant contracts worth nearly $3 million, such as the National Institute of Allergy and Infectious Diseases (NIAID) contract for developing in vitro diagnostics for biodefense and emerging infectious diseases. All of these contract awards were issued without specific set-aside designations and primarily supported COVID-19 variant monitoring, public health surveillance, and clinical decision-making efforts.
Regarding federal grant awards, Clear Labs Inc. has participated as a sub-grantee in federal grant programs supporting COVID-19 testing and surveillance efforts. The company received sub-awards from the Executive Office of the Governor of Delaware and the State of Montana Department of Health and Human Services. These sub-awards involved purchasing supplies, equipment, and services for testing SARS-CoV-2 samples, with the laboratory supporting state-level COVID-19 testing and monitoring initiatives. The grant awards demonstrate Clear Labs' ability to collaborate with state health departments in implementing critical public health testing strategies.
Clear Labs Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the VA Veterans Health Administration, valued at $16 million. This IDC, awarded in October 2022, covers COVID-19 genomic sequencing services and associated products through September 2024, with potential extensions to 2027. Under this IDC, the company has received multiple task orders to deliver COVID-19 sequencing capabilities to VA facilities, primarily in California. The contract was uniquely awarded under FAR 6.302-1, recognizing Clear Labs' proprietary DX analyzer platform as a specialized technology meeting the VA's specific requirements. The IDC supports the VA's efforts to monitor COVID-19 variants impacting veteran healthcare and inform treatment strategies, demonstrating the company's critical role in federal health technology and genomic analysis.
Quick answers
Is Clear Labs Inc. registered in SAM.gov?
Yes. Clear Labs Inc.'s SAM.gov registration is active through July 2, 2027.
How much has Clear Labs Inc. received in federal contracts?
Federal contracts obligated $404,990 to Clear Labs Inc. in fiscal year 2025 and $4,044,801 in fiscal years 2023 through 2027.
How does Clear Labs Inc. rank among federal contractors?
Clear Labs Inc. ranked #45 in PSC 6550 in FY2025.
What is Clear Labs Inc.'s most recent federal award?
Clear Labs Inc.'s most recent federal contract award is Covid-19 genomic sequencing (36C26126N0084), from Veterans Integrated Service Network 21 (VHA), on October 1, 2025.
On GovTribe
See Clear Labs Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors